Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 2, p. s532, 2025. DOI: 10.25251/skin.10.supp.532. Disponível em: https://skin.dermsquared.com/skin/article/view/3309. Acesso em: 9 may. 2026.